A Multi-center, Single-arm, Open-label, Extension Clinical Study to Evaluate the Long-term Safety and Efficacy of LBEC0101 50 mg Subcutaneous Weekly Injection When Co-administered With Methotrexate (MTX) for Additional 48 Weeks in Patients With Rheumatoid Arthritis Who Have Completed the Treatment Period of LG-ECCL002 Study.
Phase of Trial: Phase III
Latest Information Update: 24 Nov 2016
At a glance
- Drugs Etanercept (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors LG Life Sciences
- 21 Nov 2016 Status changed from not yet recruiting to recruiting.
- 28 Mar 2016 New trial record